News

Senior health science industry innovation leader joins Virginia Tech’s Fralin Biomedical Research Institute at VTC

A senior business leader in the development and translation of biomedical science innovation through the commercialization pipeline has joined Virginia Tech to facilitate the growth of the academic health sciences research enterprise through building strategic industry partnerships and facilitating commercialization of discoveries.

Sally Allain, formerly the head of Johnson & Johnson Innovation JLABS @ Washington, D.C., has been named the Chief of Health Sciences Growth and Innovation Officer with the Fralin Biomedical Research Institute at VTC and the Office of Health Sciences and Technology, said Michael Friedlander, the university’s vice president for health sciences and technology and executive director of the research institute.

Allain will be involved in all aspects of the commercialization and industry partnership enterprises specifically related to health sciences, including technology commercialization, startup companies, and research collaborations with corporate, academic, and government organizations.

She will serve as the Virginia Tech Office of Health Sciences and Technology ambassador and representative with established biotechnology industry partners such as pharmaceutical, medical device, imaging, diagnostic, and digital health companies.

“Sally Allain has an exceptional track record for developing biotech businesses and building partnerships with up-and-coming as well as established companies,” Friedlander said. “She is also an experienced and committed mentor of early-stage biotech startup entrepreneurs and has a deep understanding of the role of academic scholarship and innovation in the commercialization enterprise. She is highly regarded by colleagues in academia and industry on the global stage and can be a powerful connector for Virginia Tech faculty, staff and students with interest in working with industry partners and bringing their discoveries to the marketplace. She has made a significant impact in this capacity to strengthen the Washington, D.C., Maryland, and Virginia life sciences economies.”

In her most recent role as head of Johnson & Johnson Innovation – JLABS @ Washington, D.C., Allain set the strategic direction and oversaw all activity, including external engagement, business development, innovation sourcing, portfolio management, and operational excellence.

Allain built strategic partnerships with corporate, academic, government, and industry organizations that aim to strengthen the region’s life sciences innovation network.

Allain has long been involved with the research institute and Virginia Tech, going back to her undergraduate days at the university. She received both her bachelor’s and master’s degrees from Virginia Tech, so her return feels like a journey coming full circle.

“Seeing the strength of what Virginia Tech has built at the Fralin Biomedical Research Institute at VTC and in health sciences, along with big growth plans moving forward, I believe the organization is at an inflection point filled with opportunities,” Allain said. “I really see that growth mindset. It feels like the right time to join the university and  I’m excited to be a part of the health sciences team.”

Allain joined JLABS after serving as senior director of Strategy and Operations at Johnson & Johnson, where she played a key role in establishing a new operating model, managing global portfolios, and supporting strategic business development.

Prior to that, at within Immunology at Janssen Research & Development (Johnson & Johnson), Allain led a team responsible for overseeing global external collaboration and alliance portfolios and research operations from early discovery to early development.

“Sally Allain is the ideal person to help us to take the health sciences and technology enterprise to the next level,” Friedlander said. “She knows the innovation and commercialization ecosystem at the state, regional, national and global levels, she knows the players, she knows excellence. And most importantly, she understands at a very high level what it takes to establish formal science, health science, and biotech partnerships, initiatives, and relationships. This is a big plus for Virginia Tech. We expect amazing things ahead.”

Allain will collaborate with LINK + LICENSE + LAUNCH, which handles the larger innovation and partnerships portfolio with Virginia Tech.

In addition to a bachelor’s degree in biology and a master’s degree in microbiology/immunology from Virginia Tech, Allain earned a master’s degree in business administration from the University of California, Berkeley, Haas School of Business.

Learn more here.

Recent News

03/21/2025

Luna Labs to Expand Research and Development Operations in Charlottesville

Governor Glenn Youngkin today announced that Luna Labs USA, LLC, a product development company accelerating breakthrough solutions to multiple industries, will invest $200,000 to expand its operations in the City of Charlottesville. The company will create 20 new jobs. “Luna Labs’ expansion demonstrates Virginia’s ability to cultivate and retain innovative technology companies,” said Governor Glenn Youngkin.

03/18/2025

Committed to Innovation: Roanoke Blacksburg Innovation Alliance Replaces Verge

The Roanoke Blacksburg Innovation Alliance, formerly Verge, unveiled a major rebrand to reflect their ongoing commitment to tech-based economic advancement and their leadership in a portfolio of organizations dedicated to developing the Roanoke Blacksburg innovation ecosystem. The elements of the Roanoke Blacksburg Innovation Alliance (RBIA) include: A new name that reflects the commitment of Roanoke Blacksburg

03/14/2025

CEL-SCI’s Head and Neck Cancer Study Clears FDA Review, Eyes Commercialization Partners

CEL-SCI Corporation announced that a third-party study published on March 6, 2025 in JAMA Oncology titled “Neoadjuvant Nivolumab Plus Chemotherapy Followed by Response-Stratified Chemoradiation Therapy in HPV-Negative Head and Neck Cancer: The DEPEND Phase 2 Non-randomized Clinical Trial” provided data that support Multikine’s use as a neoadjuvant treatment in patients with tumors having low PD-L1 expression